PROPANC BIOPHARMA, INC. Cost of Revenue
PROPANC BIOPHARMA, INC. (PPCB) reported Cost of Revenue of $7.59 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2020-05-15
- PROPANC BIOPHARMA, INC. cost of goods and services sold for the quarter ending 2020-03-31 was $7.59K, a 4.73% increase year-over-year.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for the quarter ending 2019-12-31 was $7.59K, a 17.72% increase year-over-year.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for the quarter ending 2019-09-30 was $10.63K, a 31.62% increase year-over-year.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for the quarter ending 2019-06-30 was $6.29K, a 7.37% decline year-over-year.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for fiscal 2019 was $28.06K, a 8.06% decline from fiscal 2018.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for fiscal 2018 was $30.52K, a 5.27% increase from fiscal 2017.
- PROPANC BIOPHARMA, INC. cost of goods and services sold for fiscal 2017 was $28.99K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2020-03-31 | $7.59K 10-Q · filed 2020-05-15 | $15.18K derived: sum of 2 quarters · filed 2020-05-15 | $25.82K 10-Q · filed 2020-05-15 | $32.10K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $7.59K 10-Q · filed 2020-02-14 | $18.22K 10-Q · filed 2020-02-14 | $24.51K derived: sum of 3 quarters · filed 2020-02-14 | $31.76K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-09-30 | $10.63K 10-Q · filed 2019-11-14 | $16.92K derived: sum of 2 quarters · filed 2019-11-14 | $24.17K derived: sum of 3 quarters · filed 2020-05-15 | $30.62K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-06-30 | $6.29K derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-15 | $13.54K derived: sum of 2 quarters · filed 2020-05-15 | $19.98K derived: sum of 3 quarters · filed 2020-05-15 | $28.06K 10-K · filed 2019-10-15 |
| 2019-03-31 | $7.25K 10-Q · filed 2020-05-15 | $13.70K derived: sum of 2 quarters · filed 2020-05-15 | $21.77K 10-Q · filed 2020-05-15 | $28.56K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $6.45K 10-Q · filed 2020-02-14 | $14.53K 10-Q · filed 2020-02-14 | $21.31K derived: sum of 3 quarters · filed 2020-02-14 | $29.32K derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-09-30 | $8.08K 10-Q · filed 2019-11-14 | $14.87K derived: sum of 2 quarters · filed 2019-11-14 | $22.87K derived: sum of 3 quarters · filed 2019-11-14 | $29.77K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $6.79K derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-15 | $14.79K derived: sum of 2 quarters · filed 2019-10-15 | $21.69K derived: sum of 3 quarters · filed 2019-10-15 | $30.52K 10-K · filed 2019-10-15 |
| 2018-03-31 | $8.01K 10-Q · filed 2019-05-15 | $14.90K derived: sum of 2 quarters · filed 2019-05-15 | $23.73K 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $6.90K 10-Q · filed 2019-02-14 | $15.73K 10-Q · filed 2019-02-14 | ||
| 2017-09-30 | $8.83K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $28.99K 10-K · filed 2018-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |